Back to search
Non-Active Secondary Progressive Multiple Sclerosis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Non-Active Secondary Progressive Multiple Sclerosis trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Non-Active Secondary Progressive Multiple Sclerosis trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and saf…
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomi…
Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Ac…
The purpose of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine versus placebo to stop inflammation and treat disease…
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrel…
This is an observational, multicenter, single-arm, prospective study conducted in Italy